DE60322389D1 - Tend lamotrigin - Google Patents

Tend lamotrigin

Info

Publication number
DE60322389D1
DE60322389D1 DE60322389T DE60322389T DE60322389D1 DE 60322389 D1 DE60322389 D1 DE 60322389D1 DE 60322389 T DE60322389 T DE 60322389T DE 60322389 T DE60322389 T DE 60322389T DE 60322389 D1 DE60322389 D1 DE 60322389D1
Authority
DE
Germany
Prior art keywords
formulations
lamotrigin
tend
lamotrigine
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60322389T
Other languages
English (en)
Inventor
Sunil Sadanand Nadkarni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Torrent Pharmaceuticals Ltd
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Application granted granted Critical
Publication of DE60322389D1 publication Critical patent/DE60322389D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
DE60322389T 2002-06-07 2003-06-06 Tend lamotrigin Expired - Lifetime DE60322389D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38679502P 2002-06-07 2002-06-07
PCT/IN2003/000213 WO2003104192A2 (en) 2002-06-07 2003-06-06 Controlled release formulation of lamotrigine

Publications (1)

Publication Number Publication Date
DE60322389D1 true DE60322389D1 (de) 2008-09-04

Family

ID=29736213

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60322389T Expired - Lifetime DE60322389D1 (de) 2002-06-07 2003-06-06 Tend lamotrigin

Country Status (12)

Country Link
US (2) US7939102B2 (de)
EP (1) EP1513535B1 (de)
AT (1) ATE401890T1 (de)
AU (1) AU2003267808A1 (de)
BR (1) BRPI0311701B8 (de)
CA (1) CA2488868C (de)
DE (1) DE60322389D1 (de)
DK (1) DK1513535T3 (de)
ES (1) ES2311108T3 (de)
PT (1) PT1513535E (de)
RU (1) RU2328274C2 (de)
WO (1) WO2003104192A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089808A1 (de) * 2001-05-09 2002-11-14 Bayer Healthcare Ag Neue verwendung von 2-phenyl-substituierten imidazotriazinonen
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
WO2004103340A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Water dispersible tablets of lamotrigine
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
WO2005051350A2 (en) * 2003-10-28 2005-06-09 Torrent Pharmaceuticals Limited Water dispersible tablet
AU2005244329A1 (en) * 2004-04-06 2005-11-24 Rpg Life Sciences Limited Mouth dissolvable and meltable, and water dispersable delivery formulation
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
KR20070104471A (ko) * 2005-02-15 2007-10-25 재즈 파마슈티칼즈 치환된 피라진 화합물의 서방을 위한 투여형 및 그 방법
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
US20090214640A1 (en) * 2005-03-04 2009-08-27 Intelgenx Cporp. Delayed release pharmaceutical oral dosage form and method of making same
EP1906937B1 (de) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Neuartige dispergierbare tabletten zusammensetzung
AU2006299232A1 (en) * 2005-09-29 2007-04-12 Bayer Schering Pharma Aktiengesellschaft PDE inhibitors and combinations thereof for the treatment of urological disorders
US20100184769A1 (en) * 2007-06-13 2010-07-22 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
TWI547282B (zh) * 2007-07-02 2016-09-01 愛戴爾製藥股份有限公司 樂命達之口服分解錠劑組合物
US20090022789A1 (en) * 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
US20090181084A1 (en) * 2008-01-15 2009-07-16 Ta-Ping Liao Oral fast-disintegrating tablet including particles of slowly-releaseable ascorbic acid
US20090196924A1 (en) * 2008-02-04 2009-08-06 Pramod Kharwade Controlled-release lamotrigine formulations
US8133506B2 (en) 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
FR2930147B1 (fr) * 2008-04-18 2013-02-08 Flamel Tech Sa Forme orale solide dotee d'un double profil de liberation
EP2389174A4 (de) * 2009-01-22 2014-05-07 Abbot Healthcare Private Ltd Pharmazeutische zusammensetzung für chronotherapie
EP2564836A1 (de) 2009-05-20 2013-03-06 Ranbaxy Laboratories Limited Lamotriginformulierungen mit gesteuerter Freisetzung
US20110052686A1 (en) * 2009-09-03 2011-03-03 Ranbaxy Laboratories Limited Modified release lamotrigine tablets
US20130108697A1 (en) 2010-03-04 2013-05-02 Ramakant Kashinath Gundo Modified release dosage form
RU2633655C1 (ru) * 2016-05-17 2017-10-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" Устройство для дозированного вскрытия микрокапсул
CN110545818A (zh) * 2017-02-03 2019-12-06 朱比兰特医药有限公司 拉莫三嗪悬浮剂剂型

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
NL9220009A (nl) * 1991-01-30 1993-11-01 Wellcome Found In water-dispergeerbare tabletten.
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
DE60312670T2 (de) * 2002-04-23 2007-12-06 Teva Pharmaceutical Industries Ltd. Pharmazeutische zusammensetzung enthaltend lamotrigine-partikel mit definierter morphologie
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
TWI342213B (en) * 2002-07-29 2011-05-21 Glaxo Group Ltd A sustained release formulation

Also Published As

Publication number Publication date
PT1513535E (pt) 2008-10-31
AU2003267808A8 (en) 2003-12-22
BR0311701A (pt) 2005-03-08
RU2328274C2 (ru) 2008-07-10
WO2003104192A3 (en) 2004-03-11
BRPI0311701B1 (pt) 2018-05-29
CA2488868C (en) 2010-05-11
BRPI0311701B8 (pt) 2021-05-25
EP1513535A2 (de) 2005-03-16
ES2311108T3 (es) 2009-02-01
DK1513535T3 (da) 2008-11-17
US20040043996A1 (en) 2004-03-04
US7939102B2 (en) 2011-05-10
RU2004139088A (ru) 2005-11-20
EP1513535B1 (de) 2008-07-23
CA2488868A1 (en) 2003-12-18
WO2003104192A2 (en) 2003-12-18
US20110123618A1 (en) 2011-05-26
ATE401890T1 (de) 2008-08-15
AU2003267808A1 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
DE60322389D1 (de) Tend lamotrigin
IL280818A (en) Methods of production of alpha-galactosides preparations
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
EP1545558A4 (de) 1, 3, 5-triazine zur behandlung von viruserkrankungen
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
MXPA04011612A (es) Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
EP1374935A4 (de) Medizinische spritze und verfahren zu ihrer herstellung
DE60223254D1 (de) Verzögert freisetzende formulierungen von oxymorphon
AU2003245282A1 (en) Stent coatings with sustained drug release rate
DK0703786T3 (da) Anvendelse af nona- og dekapeptider til fremstilling af et lægemiddel til behandling af AIDS
IL165860A0 (en) Administration of therapeutic viruses
NO20051658L (no) Terapeutisk behandling
WO2002100152A3 (en) Solution-phase combinatiorial library synthesis and pharmaceutically active compounds produced thereby
MXPA04004306A (es) Uso de antagonistas del receptor de endotelina para el tratamiento de enfermedades tumorales.
AU2003286726A8 (en) Methods for drug discovery, disease treatment, and diagnosis using metabolomics
MXPA03009535A (es) Comprimido de meloxicam de rapida desintegracion.
MY137620A (en) Therapeutic treatment
WO2005007149A8 (de) Ambroxol für die behandlung akuter schmerzen
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
HUP0401782A2 (hu) Új, vízmentes kristályos gabapentin formák
DK1178819T3 (da) Anvendelse af GSSG-reduktase til behandling og forebyggelse af AIDS
MXPA01007952A (es) Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.
IS8356A (is) Lyfjasamsetningar, aðferðir og skammtastjórnun fyrir meðhöndlun og forvarnir á bráðum kransæðasjúkdómum
GB0216027D0 (en) New therapeutic use

Legal Events

Date Code Title Description
8364 No opposition during term of opposition